Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Ezewuiro, Obiageli ^a   Grushko, Tatyana A ^a   Kocherginsky, Masha ^a   Habis, Mohammed ^a   Hurteau, Jean A ^b   Mills, Kathryn A ^a   Hunn, Jessica ^a   Olopade, Olufunmilayo I ^a   Fleming, Gini F ^a   Romero, Iris L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; ENDOMETRIUM CANCER; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; ADENOCARCINOMA, CLEAR CELL; AGED; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FOLLOW UP; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA, CLEAR CELL; AGED; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84958213162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147145     Document Type: Article

References (33)

1. Sterne J (1957) Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (N.N.D. G.). Maroc Medical 36: 1295-1296.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. (2012) Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-1379. doi: 10.2337/dc12-0413 PMID: 22517736
3. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. (2013) Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98: 4565-4592. doi: 10.1210/jc.2013-2350 PMID: 24151290
4. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. British Medical Journal 530: 1304-1305.
5. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258. PMID: 16443869
6. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM (2009) New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625. doi: 10.2337/dc08-2175 PMID: 19564453
7. Landman GW, Kleefstra N, van Hateren KJJ, Groenier KH, Gans RO, Bilo HJ(2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326. doi: 10. 2337/dc09-1380 PMID: 19918015
8. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One 8: e71583. doi: 10.1371/journal.pone.0071583 PMID: 23936520
9. Pollak MN (2012) Investigating metformin for cancer prevention and treatment: The end of the beginning. Cancer Discovery 2: 778-790. doi: 10.1158/2159-8290.CD-12-0263 PMID: 22926251
10. Febbraro T, Lengyel E, Romero IL (2014) Old drug, new trick: Repurposing metformin for gynecologic cancers' Gynecol Oncol 135: 614-621. doi: 10.1016/j.ygyno.2014.10.011 PMID: 25455733
11. Stine JE, Bae-Jump V (2014) Metformin and gynecologic cancers. Obstet Gynecol Surv 69: 477-489. doi: 10.1097/OGX.0000000000000092 PMID: 25144611
12. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X (2014) Overweight, obesity and endometrial cancer risk: Results from a systematic review and meta-Analysis. Int J Biol Markers 29: e21-29. doi: 10.5301/jbm.5000047 PMID: 24170556
13. Rutanen EM (1998) Insulin-like growth factors in endometrial function. Gynecol Endocrinol 12: 399-406. PMID: 10065165
14. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump (2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecologic Oncology 116: 92-98. doi: 10.1016/j.ygyno.2009.09.024 PMID: 19822355
15. Zhang Z, Dong L, Sui L, Yang Y, Liu X, Yu Y, et al. (2011) Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer 21: 213-221. doi: 10.1097/IGC.0b013e318207dac7 PMID: 21270604
16. Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, et al. (2012) Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation on the mTOR pathway. Gynecologic Oncology 125: 458-469. doi: 10.1016/j.ygyno.2012.01.009 PMID: 22252099
17. Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, et al. (2013) Another surprise from Metformin: Novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther 12: 2847-2856. doi: 10.1158/1535-7163.MCT-13-0439 PMID: 24077915
18. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H (2013) Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or-independent manners. PLoS One 8: e61537. doi: 10. 1371/journal.pone.0061537 PMID: 23620761
19. Schrauwen S, Coenegrachts L, Cattaneo A, Hermans E, Lambrechts D, Armant F (2015) The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. Gynecol Oncol 138: 378-382. doi: 10.1016/j.ygyno.2015.06.006 PMID: 26050920
20. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al. (2014) Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 132: 438-442. doi: 10.1016/j.ygyno.2013.11. 021 PMID: 24269517
21. Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, et al. (2014) Metformin use and endometrial cancer survival. Gynecol Oncol 132: 236-240. doi: 10.1016/j.ygyno.2013.10.026 PMID: 24189334
22. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64: 252-271. doi: 10.3322/caac.21235 PMID: 24890451
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377-381. doi: 10.1016/j.jbi.2008.08.010 PMID: 18929686
24. Ho AM, Dion PW, Ng CS, Karmakar MK (2013) Understanding immortal time bias in observational cohort studies. Anaesthesia 68: 126-130. doi: 10.1111/anae.12120 PMID: 23298346
25. lliooulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Research 71: 3196-3201. doi: 10.1158/0008-5472.CAN-10-3471 PMID: 21415163
26. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of Clinical Oncology 27: 3297-3302. doi: 10.1200/JCO.2009.19.6410 PMID: 19487376
27. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579-591. PMID: 15286738
28. Schuler KM, Rambally BS, Difurio MJ, Gehrig PA, Bae-Jump V (2013) A preoperative window study of metformin for the treatment of endometrial cancer. Journal of Clinical Oncology Supplemental; abstract 5519.
29. Soliman PT, Broaddus R, Westin S, Iglesias D, Runsell M, Schmandt R (2013) Phase 0 study: Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer. Society of Gynecologic Oncologists: Supplemental 15-Abstract.
30. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, et al. (2014) Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 134: 607-614. doi: 10.1016/j.ygyno.2014.06.014 PMID: 24972190
31. Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M (2014) Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial. Cancer: doi: 10.1002/cncr.28853
32. Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM (2014) Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer' A systematic review and meta-Analysis of cohort studies. Gynecol Oncol 135: 163-171. doi: 10.1016/j.ygyno.2014.07.095 PMID: 25072931
33. NIH http://clinicaltrials.gov/.